2-amino-6-ethylnicotinonitrile | 1026039-54-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-amino-6-ethylnicotinonitrile
• 英文别名: 2-amino-6-ethylpyridine-3-carbonitrile
• CAS: 1026039-54-2
• 化学式: C₈H₉N₃
• mdl: MFCD18384478
• 分子量: 147.18
• InChiKey: WCIDEVCXDIHZEJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  62.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-amino-6-ethylnicotinonitrile 以 溶剂黄146 、 甲苯 为溶剂， 反应 4.5h， 生成 7-ethyl-N-(5-methyl-2-phenylsulfanyl-phenyl)pyrido[2,3-d]pyrimidin-4-amine
  参考文献：
  名称：

  Novel Hepatitis C virus replicon inhibitors: Synthesis and structure–activity relationships of fused pyrimidine derivatives

  摘要：

  The synthesis of several pyrido[2,3-d] pyrimidine and pyrimido[4,5-d] pyrimidine analogs is described with one such analog possessing subnanomolar potency in both genotype 1a and 1b cell culture HCV replicon assays. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.01.096
• 作为产物：
  描述：

  2-氯-6-甲基-3-吡啶甲腈 在 氨 、 sodium hydride 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 28.25h， 生成 2-amino-6-ethylnicotinonitrile
  参考文献：
  名称：

  通过合理的针对性重用方法发现基于碳酸酐酶抑制剂的新型潜在抗感染化合物

  摘要：

  在学术界，化合物回收代表了另一种药物发现策略，可从内部可用的化合物库中识别新的药物靶标。在此，我们报告了一种合理的基于目标药物的重新定位方法的应用，该方法可为我们内部的化合物收集找到多种应用。碳酸酐酶（CA，EC 4.2.1.1）金属酶超家族被确定为我们化合物的潜在目标。彻底验证的对接筛选方案与针对各种CA家族和同工型的体外测定相结合，使我们能够鉴定出两种史无前例的化学型作为CA抑制剂。

  DOI：

  10.1002/cmdc.201600180

文献信息

• 6, 11-bridged tricyclic macrolides
  申请人：Or Sun Yat

  公开号：US20070082853A1

  公开（公告）日：2007-04-12

  The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.

  本发明公开了具有以下结构的化合物I，或其药学上可接受的盐、酯或前药：这些化合物具有抗菌性能。本发明还涉及包括上述化合物的药物组合物，用于治疗需要抗生素治疗的受试者。该发明还涉及通过给受试者施用包含本发明化合物的药物组合物来治疗受试者的细菌感染的方法。该发明还包括制备本发明化合物的方法。
• [EN] SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER<br/>[FR] COMPOSÉS D'OXOISOINDOLINE SUBSTITUÉS POUR LE TRAITEMENT DU CANCER
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2021194914A1

  公开（公告）日：2021-09-30

  Disclosed are compounds of Formula (I) or a salt thereof, wherein Ring A is a carbon-linked ring; and Ring A, R1, and n are defined herein. Also disclosed are methods of using such compounds to inhibit Helios protein, and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

  揭示了化合物的结构式（I）或其盐，其中环A是一个碳链环；环A，R1和n在此处有定义。还揭示了使用这些化合物抑制Helios蛋白的方法，以及包含这些化合物的药物组合物。这些化合物在治疗病毒感染和增生性疾病（如癌症）方面具有用途。
• 3,6-BRIDGED TYLOSIN DERIVATIVES
  申请人：Qiu Yao-Ling

  公开号：US20080039406A1

  公开（公告）日：2008-02-14

  The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.

  本发明公开了化合物I的结构，或其药学上可接受的盐、酯或前药：这些化合物具有抗菌性能。本发明还涉及包含上述化合物的药物组合物，用于给需要抗生素治疗的受试者进行治疗。本发明还涉及通过给受试者施用包含本发明化合物的药物组合物来治疗受试者的细菌感染的方法。本发明还包括制备本发明化合物的方法。
• BRIDGED CARBAMATE MACROLIDES
  申请人：Kim Heejin

  公开号：US20080027012A1

  公开（公告）日：2008-01-31

  The present invention discloses compounds of formulae (I) and (II) or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.

  本发明公开了式(I)和(II)的化合物或其药学上可接受的盐、酯或前药：这些化合物具有抗菌性能。本发明还涉及含有上述化合物的药物组合物，用于治疗需要抗生素治疗的受试者。该发明还涉及通过给予含有本发明化合物的药物组合物来治疗受试者的细菌感染的方法。该发明还包括制备本发明化合物的方法。
• C-9 ALKENYLIDINE BRIDGED MACROLIDES
  申请人：Phan Ly Tam

  公开号：US20080119418A1

  公开（公告）日：2008-05-22

  The present invention discloses compounds of formulae (I), (II) or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.

  本发明揭示了以下化合物的公式（I），（II）或其药学上可接受的盐，酯或前药：具有抗菌性质。本发明还涉及包括上述化合物的制药组合物，用于治疗需要抗生素治疗的受体。本发明还涉及通过给予包含本发明化合物的制药组合物来治疗受体的细菌感染的方法。本发明还包括制备本发明化合物的方法。